Antineoplastic drugs

Skin Cancer Drugs Global Market Report 2021: Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma - ResearchAndMarkets.com

Retrieved on:

Friday, June 25, 2021

Pharmaceutical, Health, Oncology, Clinical medicine, Medicine, Health, Antineoplastic drugs, Cancer, Oncology, Carcinoma, Actinic keratosis, Bristol Myers Squibb, Basal-cell carcinoma, Skin cancer, Melanoma

Major players in the global skin cancer drugs market are Novartis AG, Bristol Myers Squibb, Eli Lilly, Meda, and Sun Pharmaceutical Industries Ltd.

Key Points:

Major players in the global skin cancer drugs market are Novartis AG, Bristol Myers Squibb, Eli Lilly, Meda, and Sun Pharmaceutical Industries Ltd.
The skin cancer drugs market consists of sales of skin cancer drugs.
Skin cancer can be of various types including actinic keratoses, basal cell carcinoma, squamous cell carcinoma or melanoma.
To treat such high cases of skin cancer, more number of new innovative skin cancer drugs is being manufactured.

DGAP-News: MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Retrieved on:

Friday, June 25, 2021

"Tafasitamab in combination with lenalidomide represents an important new targeted treatment option for patients with relapsed or refractory DLBCL," said Dr. Malte Peters, Chief Research & Development Officer, MorphoSys.

Key Points:

"Tafasitamab in combination with lenalidomide represents an important new targeted treatment option for patients with relapsed or refractory DLBCL," said Dr. Malte Peters, Chief Research & Development Officer, MorphoSys.
"Patients with relapsed or refractory DLBCL have limited treatment options and often face a poor prognosis.
There is an urgent need for effective therapies and if approved, this combination could provide patients in Europe with an important new therapeutic option."
MorphoSys and Incyte co-commercialize tafasitamab under the brand name Monjuvi(R) in the United States.

Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Retrieved on:

Friday, June 25, 2021

Tafasitamab in combination with lenalidomide represents an important new targeted treatment option for patients with relapsed or refractory DLBCL, said Dr. Malte Peters, Chief Research & Development Officer, MorphoSys.

Key Points:

Tafasitamab in combination with lenalidomide represents an important new targeted treatment option for patients with relapsed or refractory DLBCL, said Dr. Malte Peters, Chief Research & Development Officer, MorphoSys.
Patients with relapsed or refractory DLBCL have limited treatment options and often face a poor prognosis.
Incyte and MorphoSys share global development rights to tafasitamab and Incyte has exclusive commercialization rights to tafasitamab outside the United States.
Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma.

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy

Retrieved on:

Friday, June 25, 2021

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Drugs, Medicine, Antineoplastic drugs, Orphan drugs, Breakthrough therapy, Bristol-Myers Squibb, Nivolumab, Chemoradiotherapy, Cabozantinib, Neoadjuvant therapy, Renal cell carcinoma

For many patients with localized esophageal or gastroesophageal junction cancer, the risk of recurrence is high, even after neoadjuvant chemoradiotherapy and surgery.

Key Points:

For many patients with localized esophageal or gastroesophageal junction cancer, the risk of recurrence is high, even after neoadjuvant chemoradiotherapy and surgery.
This leaves patients in need of additional treatment options, said Ian M. Waxman, M.D., development lead, gastrointestinal cancers, Bristol Myers Squibb.
Opdivo is approved in the United States for the adjuvant treatment of completely resected esophageal or GEJ cancer with residual pathologic disease in patients who have received neoadjuvant CRT.
OPDIVO (nivolumab), in combination with cabozantinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

Research showed that InxMed FAK Inhibitor (IN10018) Overcomes Drug Resistance of KRAS G12C inhibitors and Synergizes with KRAS G12C inhibitors in Treating Cancer

Retrieved on:

Friday, June 25, 2021

Chemical compounds, Piperazines, KRAS, Organic compounds, Antineoplastic drugs, Breakthrough therapy, Orphan drugs, Sotorasib, Targeted covalent inhibitors, Adagrasib

It can simultaneously reduce the extent of drug resistance to improve treatment outcomes of KRAS G12C inhibitors.

Key Points:

It can simultaneously reduce the extent of drug resistance to improve treatment outcomes of KRAS G12C inhibitors.
Diverse CDX and PDX models of KRAS G12C mutant cancers were tested and synergistic benefits from the combination therapy of KRAS G12C inhibitors (AMG510 or MRTX849) and FAK inhibitor (IN10018) were consistently observed.
Mechanistically, it is found that aberrant FAKYAP signaling leading to the development of KRAS G12C inhibitor resistance.
Dr. Zaiqi Wang, InxMed's Chairman and CEO, said "This study showed that FAK inhibitor (IN10018) overcomes drug resistance of KRAS G12C inhibitors and provides a potential innovative combination therapy to improve treatment outcomes for KRAS G12C mutant cancers.

SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined with Opdivo

Retrieved on:

Thursday, June 24, 2021

Drugs, Health sciences, Health care, Bristol-Myers Squibb, Antineoplastic drugs, Breakthrough therapy, Orphan drugs, Monoclonal antibodies, Nivolumab, Bristol Myers Squibb

The study details are as follows:

Key Points:

The study details are as follows:
Four evaluable male patients, aged approximately 67.3 + 4.1 (standard deviation), received GPS plus nivolumab for at least one month.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications.
Opdivo is a registered trademark of Bristol Myers Squibb, and is not a trademark of SELLAS.
The manufacturer of this brand is not affiliated with and does not endorse SELLAS or its products.

Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox®

Retrieved on:

Wednesday, June 23, 2021

Cancer, Clinical medicine, Medicine, Antineoplastic drugs, Anthracyclines, Doxorubicin, Teratogens, Bladder cancer, Immunotherapy, Chemotherapy

LAWRENCEVILLE, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announces that its new wholly owned subsidiary, Celsion GmbH, will manage all current and future investigator-sponsored development of ThermoDox, the Companys proprietary heat-activated liposomal encapsulation of doxorubicin.

Key Points:

LAWRENCEVILLE, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announces that its new wholly owned subsidiary, Celsion GmbH, will manage all current and future investigator-sponsored development of ThermoDox, the Companys proprietary heat-activated liposomal encapsulation of doxorubicin.
A clinical project at the National Institutes of Health to evaluate ThermoDox plus the chemotherapy drug mitomycin in bladder cancer.
Celsion GmbHs long-term objective is to seek partnerships that will maximize the potential of ThermoDox, ultimately providing value to the parent company.
Celsion also has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies.

Orum Therapeutics Closes $84 Million Series B Financing to Advance Novel Targeted Protein Degrader Payloads into Clinical Trials for Cancer

Retrieved on:

Wednesday, June 23, 2021

Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Cancer, Antiestrogens, Clinical medicine, Antineoplastic drugs, Selective estrogen receptor degraders, Drugs, Causes of death

Orum Therapeutics , a biotech company pioneering the development of targeted protein degraders to treat cancer, today announced the close of a $84 million Series B financing.

Key Points:

Orum Therapeutics , a biotech company pioneering the development of targeted protein degraders to treat cancer, today announced the close of a $84 million Series B financing.
These first-in-class targeted ADC protein degraders have the potential to deliver precise and catalytic tumor-killing action to improve cancer treatment.
We believe our AnDC platform overcomes the lack of diversity in ADC payloads and the limitations of current targeted protein degrader technologies.
Orum Therapeutics is pioneering the development of tumor-directed targeted protein degraders to improve the treatment of cancer.

First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Retrieved on:

Wednesday, June 23, 2021

The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC).

Key Points:

The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC).
The primary endpoint of the study is radiographic progression-free survival (rPFS), and overall survival (OS) is a secondary endpoint.
Talazoparib is currently approved under the brand name TALZENNA for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.
Talazoparib is being evaluated in several ongoing clinical trials in prostate cancer, as well as other novel combinations with targeted therapies in various solid tumors.

Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy

Retrieved on:

Monday, June 21, 2021

Clinical medicine, Medicine, Cancer, Cancer treatments, Antineoplastic drugs, Immutep, Chemotherapy, Eftilagimod alpha

INSIGHT-003 will be an investigator-initiated trial conducted by the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt.

Key Points:

INSIGHT-003 will be an investigator-initiated trial conducted by the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt.
Patients will receive 30 mg doses of efti every two weeks for 24 weeks in conjunction with standard of care chemotherapy plus anti-PD-1 therapy.
Thereafter, patients will enter a maintenance phase and receive either efti alone or in double or continued triple combination with anti-PD-1 therapy.
Commenting on the new trial, Immutep CEO Marc Voigt said: Testing efti as part of a triple combination therapy is an important and exciting expansion of our development program.